Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 214

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 214
---
golden parachute” compensation arrangements for our
named executive officers, as disclosed in the table entitled “Golden Parachute Compensation” in the section of this Proxy Statement entitled “Quantification of Potential Payments to Certain Named Executive Officers in Connection with the Merger” beginning on page [●].

We are asking our stockholders to indicate their approval of the various change of
control payments which our named executive officers will or may be eligible to receive in connection with the Divestiture. These payments are set forth in the table entitled “Golden Parachute Compensation” on page [●] of this
Proxy Statement and the accompanying footnotes. The arrangements pursuant to which these compensation payments may be made have previously formed part of the Company’s overall compensation program for its named executive officers, which has
been disclosed to our stockholders as part of the Compensation Discussion and Analysis and related sections of our annual meeting proxy statements. These historical arrangements were adopted and approved by the Compensation Committee, which is
composed solely of independent directors, and are believed to be reasonable and in line with marketplace norms. Accordingly we are seeking approval of the following resolution:

“RESOLVED, that the stockholders of the Company approve, solely on an advisory, non-binding basis,
the golden parachute compensation which may be paid to the Company’s named executive officers in connection with the Divestiture, as disclosed pursuant to Item 402(t) of Regulation S-K in the table
entitled “Golden Parachute Compensation” in the section entitled “Quantification of Potential Payments to Certain Named Executive Officers in Connection with the Merger” in the Company’s proxy statement.”

Stockholders should note that this non-binding proposal regarding certain Divestiture-related executive
compensation arrangements is merely an advisory vote which will not be binding on the Company, our board of directors or Kaken. We will treat approval of the advisory vote as having been obtained if this proposal receives the affirmative vote, in
person or by proxy, of the majority of the voting power of the shares present in person or represented by proxy at the meeting and entitled to vote on the subject matter. Further, the underlying plans and arrangements are contractual in nature and
not, by their terms, subject to stockholder approval. Accordingly, regardless of the outcome of the advisory vote, if the Divestiture is consummated, our named executive officers will be eligible to receive the various change of control payments in
accordance with the terms of conditions applicable to those payments.

THE AADI BOARD OF DIRECTORS RECOMMENDS